86 related articles for article (PubMed ID: 20206921)
1. Consecutive low doses of cyclophosphamide preferentially target Tregs and potentiate T cell responses induced by DNA PLG microparticle immunization.
Barbon CM; Yang M; Wands GD; Ramesh R; Slusher BS; Hedley ML; Luby TM
Cell Immunol; 2010; 262(2):150-61. PubMed ID: 20206921
[TBL] [Abstract][Full Text] [Related]
2. Repeated immunization with plasmid DNA formulated in poly(lactide-co-glycolide) microparticles is well tolerated and stimulates durable T cell responses to the tumor-associated antigen cytochrome P450 1B1.
Luby TM; Cole G; Baker L; Kornher JS; Ramstedt U; Hedley ML
Clin Immunol; 2004 Jul; 112(1):45-53. PubMed ID: 15207781
[TBL] [Abstract][Full Text] [Related]
3. Tumor-specific chemoimmunotherapy of murine fibrosarcoma using tumor-specific transplantation antigen, cyclophosphamide, and interleukin-2.
Naito K; Nomi S; Komichi H; Ueda Y; Yamagishi H; Oka T; Pellis NR; Kahan BD
Cancer Detect Prev; 1992; 16(5-6):321-7. PubMed ID: 1361881
[TBL] [Abstract][Full Text] [Related]
4. In vivo electroporation enhances the potency of poly-lactide co-glycolide (PLG) plasmid DNA immunization.
Barbon CM; Baker L; Lajoie C; Ramstedt U; Hedley ML; Luby TM
Vaccine; 2010 Nov; 28(50):7852-64. PubMed ID: 20943208
[TBL] [Abstract][Full Text] [Related]
5. T regulatory cells in cancer: recent advances and therapeutic potential.
Elkord E; Alcantar-Orozco EM; Dovedi SJ; Tran DQ; Hawkins RE; Gilham DE
Expert Opin Biol Ther; 2010 Nov; 10(11):1573-86. PubMed ID: 20955112
[TBL] [Abstract][Full Text] [Related]
6. Synergistic effect of metronomic dosing of cyclophosphamide combined with specific antitumor immunotherapy in a murine melanoma model.
Hermans IF; Chong TW; Palmowski MJ; Harris AL; Cerundolo V
Cancer Res; 2003 Dec; 63(23):8408-13. PubMed ID: 14679003
[TBL] [Abstract][Full Text] [Related]
7. Gamma delta T cells in normal spleen assist immunized alpha beta T cells in the adoptive cell transfer of contact sensitivity. Effect of Bordetella pertussis, cyclophosphamide, and antibodies to determinants on suppressor cells.
Askenase PW; Szczepanik M; Ptak M; Paliwal V; Ptak W
J Immunol; 1995 Apr; 154(8):3644-53. PubMed ID: 7706708
[TBL] [Abstract][Full Text] [Related]
8. Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells.
Nagayama Y; Hase W; Motoyoshi Y; Saitoh O; Sogawa R; Nakao K
Oncol Rep; 2007 May; 17(5):1269-73. PubMed ID: 17390075
[TBL] [Abstract][Full Text] [Related]
9. High-dose cyclophosphamide-mediated anti-tumor effects by the superior expansion of CD44(high) cells after their selective depletion.
Hong SH; Yoon IH; Kim YH; Yang SH; Park MJ; Nam HY; Kim B; Kim Y; Park CS; Park CG
Immunobiology; 2010 Mar; 215(3):182-93. PubMed ID: 19464751
[TBL] [Abstract][Full Text] [Related]
10. Improvement of antitumor effect of intratumoral injection of immature dendritic cells into irradiated tumor by cyclophosphamide in mouse colon cancer model.
Son CH; Shin DY; Kim SD; Park HS; Jung MH; Bae JH; Kang CD; Yang K; Park YS
J Immunother; 2012 Oct; 35(8):607-14. PubMed ID: 22996366
[TBL] [Abstract][Full Text] [Related]
11. Erbb2 DNA vaccine combined with regulatory T cell deletion enhances antibody response and reveals latent low-avidity T cells: potential and limits of its therapeutic efficacy.
Rolla S; Ria F; Occhipinti S; Di Sante G; Iezzi M; Spadaro M; Nicolò C; Ambrosino E; Merighi IF; Musiani P; Forni G; Cavallo F
J Immunol; 2010 Jun; 184(11):6124-32. PubMed ID: 20435927
[TBL] [Abstract][Full Text] [Related]
12. Induction of multiepitopic and long-lasting immune responses against tumour antigens by immunization with peptides, DNA and recombinant adenoviruses expressing minigenes.
Durántez M; López-Vázquez AB; de Cerio AL; Huarte E; Casares N; Prieto J; Borrás-Cuesta F; Lasarte JJ; Sarobe P
Scand J Immunol; 2009 Feb; 69(2):80-9. PubMed ID: 19144076
[TBL] [Abstract][Full Text] [Related]
13. Enhanced TNP-reactive helper T cell activity and its utilization in the induction of amplified tumor immunity that results in tumor regression.
Fujiwara H; Moriyama Y; Suda T; Tsuchida T; Shearer GM; Hamaoka T
J Immunol; 1984 Mar; 132(3):1571-7. PubMed ID: 6198397
[TBL] [Abstract][Full Text] [Related]
14. Identification of a ras oncogene peptide that contains both CD4(+) and CD8(+) T cell epitopes in a nested configuration and elicits both T cell subset responses by peptide or DNA immunization.
Bristol JA; Orsini C; Lindinger P; Thalhamer J; Abrams SI
Cell Immunol; 2000 Nov; 205(2):73-83. PubMed ID: 11104579
[TBL] [Abstract][Full Text] [Related]
15. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells.
Salem ML; Kadima AN; El-Naggar SA; Rubinstein MP; Chen Y; Gillanders WE; Cole DJ
J Immunother; 2007 Jan; 30(1):40-53. PubMed ID: 17198082
[TBL] [Abstract][Full Text] [Related]
16. gamma delta T cells in normal murine spleen assist immunized alpha beta T cells in the adoptive cell transfer of contact sensitivity: effect of Bordetella pertussis. Cyclophosphamide, and antisuppressor T cell monoclonal antibodies.
Askenase PW; Ptak W; Szczepanik M
Int Arch Allergy Immunol; 1995; 107(1-3):363. PubMed ID: 7613173
[No Abstract] [Full Text] [Related]
17. Chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs.
Correale P; Del Vecchio MT; La Placa M; Montagnani F; Di Genova G; Savellini GG; Terrosi C; Mannucci S; Giorgi G; Francini G; Cusi MG
J Immunother; 2008; 31(2):132-47. PubMed ID: 18481383
[TBL] [Abstract][Full Text] [Related]
18. Low dose cyclophosphamide: Mechanisms of T cell modulation.
Madondo MT; Quinn M; Plebanski M
Cancer Treat Rev; 2016 Jan; 42():3-9. PubMed ID: 26620820
[TBL] [Abstract][Full Text] [Related]
19. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action.
Sharabi A; Azulai H; Sthoeger ZM; Mozes E
Immunology; 2007 Jun; 121(2):248-57. PubMed ID: 17346282
[TBL] [Abstract][Full Text] [Related]
20. Some characteristics of the cyclophosphamide-induced immunopotentiating cells in the spleen of mice bearing a large MOPC-315 tumor.
Mokyr MB; Ye QW
Cancer Res; 1985 Oct; 45(10):4932-9. PubMed ID: 4027979
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
